7 stories found
Multiple companies, including Shake Shack, Helmerich & Payne, and Sempra, have published their earnings previews for the first, second, and fourth quarters of 2026.
EyePoint Pharmaceuticals is targeting mid-2026 for topline data release for its drug DURAVYU, currently in Phase III trials for wet AMD and DME.
Investors are anticipating the Q4 2025 earnings report for EyePoint Pharmaceuticals, with a preview now available.
Multiple companies have released their recent financial performance, detailing GAAP or Non-GAAP earnings per share and revenue figures. These reports indicate whether the companies met, beat, or missed analyst expectations for their latest reporting period.
Eyepoint Pharmaceuticals has announced its fourth-quarter earnings, with key highlights from the earnings call.
EyePoint Pharmaceuticals has filed a lawsuit against Ocular Therapeutix, alleging claims related to its lead asset.